Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Intact Vascular to Sponsor Post-Angioplasty Dissection Symposium at 2019 New Cardiovascular Horizons Conference

May 20, 2019

WAYNE, Pa.--(BUSINESS WIRE)--May 20, 2019--

Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the schedule of key presentations to be featured during a lunch symposium at the 2019 New Cardiovascular Horizons (NCVH) Conference, May 29 th through 31 st at The Roosevelt New Orleans in New Orleans, Louisiana.

Recently FDA-approved for above-the-knee interventions, the Tack Endovascular System is a first-of-its-kind dissection repair device implanted post-angioplasty to resolve dissections in patients with peripheral arterial disease (PAD). Balloon angioplasty, whether performed with plain or drug-coated balloons, inherently injures the vessel wall, creating dissections that may inhibit blood flow and promote thrombosis formation. Despite the prevalence of dissections, they are frequently underdiagnosed and left untreated, often leading to further complications and compromised patient outcomes.

“Post-angioplasty dissections can have a significant clinical impact as demonstrated by high rates of restenosis and re-intervention,” said Bruce Shook, President and CEO of Intact Vascular. “We are pleased to have such a robust program this year at the NCVH Conference, showcasing the importance of treating dissections with the Tack Endovascular System, a minimal metal solution that improves angioplasty outcomes and preserves future treatment options for patients.”

The lunch symposium, “Precision Dissection Repair with the Tack Endovascular System: Evidence and Early Experience”, will be held from 12:00 to 12:55PM on Wednesday, May 29 th in the Blue Room, Lobby Level. The symposium will feature presentations by Dr. George Adams, Dr. Ehrin Armstrong, Dr. Mohammad (Mac) Ansari and Dr. Nicolas Shammas.

Additionally, Dr. Ehrin Armstrong will present, “ Tack Endovascular Device: TOBA II Trial ” on Thursday, May 30 th at 2:44PM in the Crescent City Ballroom, Mezzanine Level.

Visit Intact Vascular at booth #206 or attend one of the presentations to learn more about the Tack Endovascular System.

About Intact Vascular and the Tack Endovascular System

Intact Vascular is a privately held medical device company that develops minimally- invasive peripheral vascular products. The Tack Endovascular System is designed to repair dissections following peripheral balloon angioplasty. Pre-loaded with six self-expanding nitinol implants for above-the-knee (ATK) interventions, the Tack Endovascular System can be deployed to treat multiple dissections using a single catheter and leaving behind >70% less metal than stents. 1 Additionally, the Tack Endovascular System is designed to minimize vessel inflammation, promote healing, improve outcomes and preserve future treatment options for peripheral arterial disease patients. Visit www.intactvascular.com for more information.

Intact Vascular Clinical Program

Intact Vascular is sponsoring three clinical trials to evaluate its Tack Endovascular System: TOBA II, TOBA II BTK and TOBA III. TOBA II is investigating the combination of the Tack ® implant with plain angioplasty balloons and the BD Interventional Lutonix ® drug-coated balloon (DCB) in arteries above the knee and has completed its primary endpoint analysis. TOBA II BTK has completed enrollment and is investigating the combination of the Tack implant with plain balloon angioplasty in the arteries below the knee. TOBA III has completed enrollment in Europe and is investigating the combination of the Tack implant with the Medtronic IN.PACT ® Admiral ® (DCB), with a long lesion subset.

This press release contains “forward-looking statements” concerning the development of Intact Vascular’s products, the benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Intact Vascular undertakes no obligation to update any forward-looking statements for any reason.

1 Bosiers M, Scheinert D, Hendricks JMH et al. Results from the Tack Optimized Balloon Angioplasty (TOBA) study demonstrate the benefits of minimal metal implants for dissection repair after angioplasty. J Vasc Surg 2016;64:109-16.

Tack Endovascular System ® and Tack ® are registered trademarks of Intact Vascular, Inc.
Lutonix ® is a registered trademark of BD Interventional.
IN.PACT ® and Admiral ® are registered trademarks of Medtronic, Inc.
The Tack Endovascular System ® is CE Mark Authorized under EC Directive 93/42/EEC.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190520005012/en/

CONTACT: Intact Vascular, Inc.

Andrea Dunkle, 1-484-253-1048



SOURCE: Intact Vascular, Inc.

Copyright Business Wire 2019.

PUB: 05/20/2019 07:00 AM/DISC: 05/20/2019 07:00 AM


All contents © copyright 2019 The Associated Press. All rights reserved.